Compare Apple Inc (AAPL) vs Abbott Laboratories (ABT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Abbott Laboratories — how do they compare? Apple Inc trades at $312.84 (market cap $4.56T), while Abbott Laboratories trades at $94.63 (market cap $166.94B). The key difference: Apple Inc is far larger — about 27.3× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| AAPL | ABT | |
|---|---|---|
Market Cap | $4.56T | $166.94B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $136.62 |
52-Week Low | $202.38 | $82.57 |
Enterprise Value | $4.58T | $193.69B |
Dividend Yield | 0.35% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $310.66, down 0.64% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 26.91% net margin and consistent earnings beats. Revenue grew to $416.16B in 2025, and analyst consensus is a Buy with a $329.62 price target. Recent news highlights AI potential via 2.5B active devices and Gemini partnership, though store closures and union disputes pose headwinds.
The stock offers upside to consensus targets with robust cash flow and profitability, but high valuations (P/E 37.61) and competitive pressures warrant caution. Near-term focus is on Q2 2026 earnings against a $1.88 EPS expectation, with institutional activity mixed amid broader market rotation concerns.
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →
